Creative Medical Technology Holdings reveals stem cell product success
Biotechnology company Creative Medical Technology Holdings has announced new data which demonstrates the superior immune modulatory ability of its AmnioStem stem cell product when compared to other stem cell types.
The company compared its product to bone marrow, adipose tissue, and placental tissue mesenchymal stem cells. The data generated at its BioLabs research facility in San Diego showed that AmnioStem cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12.
Creative Medical Technology Holdings co-founder and chief scientific officer Dr Thomas Ichim said: “Control of molecules such as TNF-alpha represents a multi-billion dollar market. Currently drugs like Humira, Remicade, and Embrel, which are antibodies blocking the TNF-alpha pathway, have sales of over $30bn per year.
“Using cells as drugs represents a more viable alternative to existing approaches because the stem cells not only reduce inflammation, but also have ability to induce healing of injured tissue.”
Ichim has overseen the FDA clearance and clinical trials of several cell therapies. Creative Medical Technology Holdings is currently preparing an Investigational New Drug application with the FDA for use of its AmnioStem stem cell product for treatment of radiation toxicity.
The company’s president and CEO Timothy Warbington said: “We are extremely excited about our data, which positions Creative Medical Technology Holdings as a force in the autoimmune market.
“In addition to treatment of stroke and radiation toxicity, autoimmune diseases that may benefit from use of AmnioStem technology include Type 1 diabetes, rheumatoid arthritis, multiple sclerosis, and lupus.
“I am thankful for our collaborative network of scientists, scientific advisors, and intellectual property advisors, which are currently working in expanding the intellectual property portfolio surrounding this new cell type.”
The AmnioStem stem cell is covered by an issued US Patent, exclusively licensed from the University of California by the company in 2016.